Margarita Fallena, MD
Rheumatology · Dallas, TXNPI 1760686737
Payments from drug & device makers
Across 357 payments — averaging $1368.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$298K
- Amgen$104K
- UCB SA$64K
- GSK$19K
- AbbVie$1K
- Novartis$771
- plus $2K from 22 others
Across 3 payments — averaging $497.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 28 | $297,888 |
| Amgen(2 entities) | 52 | $104,176 |
| UCB SA | 11 | $63,543 |
| GSK | 23 | $18,609 |
| AbbVie | 65 | $1,374 |
| Novartis | 44 | $771 |
| Pfizer | 61 | $731 |
| UCB, Inc. | 11 | $259 |
| Johnson & Johnson(2 entities) | 20 | $244 |
| ANI Pharmaceuticals, Inc. | 4 | $108 |
| Lilly USA, LLC | 5 | $99 |
| Boehringer Ingelheim | 4 | $86 |
| Fresenius Kabi USA, LLC | 3 | $69 |
| E.r. Squibb & Sons, L.L.C. | 4 | $69 |
| Genentech USA, Inc. | 3 | $56 |
| AstraZeneca | 2 | $56 |
| Mallinckrodt Hospital Products Inc. | 3 | $46 |
| Aurinia Pharma U.S., Inc. | 2 | $46 |
| Hospira, Inc. | 3 | $37 |
| Mallinckrodt Enterprises LLC | 1 | $34 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $29 |
| Octapharma USA, Inc. | 1 | $26 |
| Scilex Pharmaceuticals Inc. | 1 | $23 |
| Janssen Scientific Affairs, LLC | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Sanofi | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Zimmer Biomet | 1 | $14 |
How this compares
$488,468 in reported general payments places this provider in the 90th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Dallas
- John CushDallas$3.9M
- Stanley CohenDallas$1.9M
- David KarpDallas$788K
- Sharad LakhanpalDallas$718K
- Zoran KurepaDallas$483K
- Dianne PetroneDallas$437K
- Giovanni GeslaniDallas$415K
- Kathryn DaoDallas$381K
- Pedro CastilloDallas$379K
- Paul PickrellAustin$40.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.